在痴呆症中使用抗抑郁药:评估针对脆弱人群的有效策略
Mariagiovanna Cozza1, Filippo Luca Fimognari2, Alberto Castagna3
1UOC Intermediate-Long Term Care Budrio Hospital, Integration Department, Italy.
Neuroscience and biobehavioral reviews
|August 18, 2025
概括
抑郁症与痴呆症有关,在诊断前,诊断期间或诊断后出现. 本综述审查了痴呆症患者的抗抑郁药的使用情况,倡导个性化的老年病评估,以平衡风险和益处.
科学领域:
- 老年医学 老年医学
- 神经学 神经学
- 精神病学是一个精神病学.
背景情况:
- 抑郁症是痴呆症中显著的并发症,可能表明风险,早期症状或进展.
- 它影响各种类型的痴呆症,包括阿尔茨海默氏症,血管性,莱维体和前性痴呆症.
- 准确的诊断和管理需要了解抑郁症状的时间和背景.
研究的目的:
- 批判性地审查抗抑郁药在痴呆患者抑郁症管理中的作用.
- 为抗抑郁药物使用提供一个新的视角,强调个性化,基于证据的决策.
- 强调多维老年病学评估对于平衡治疗效益和风险的重要性.
主要方法:
- 这项研究是一个叙事性综述.
- 它批判性地检查了关于在痴呆症中使用抗抑郁药物的现有文献.
- 审查的重点是需要进行全面的老年医疗评估.
主要成果:
- 非药物和心理社会干预通常是痴呆症抑郁症的第一线治疗方法.
- 抗抑郁药的使用是常见的,但往往缺乏强有力的证据,并为认知能力下降的老年人带来风险.
- 多维老年医学评估对于明智的治疗决策至关重要.
结论:
- 在痴呆症患者中使用抗抑郁药需要仔细考虑个体需求和潜在风险.
- 临床医生应优先考虑全面的老年病评估,以指导个性化,基于证据的治疗策略.
- 平衡抗抑郁药的益处和风险对于优化这种脆弱人群的护理至关重要.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
344
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:25Antidepressant Drugs: Overview
750
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
750
01:28Drug Therapy
97
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
97
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
568
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
568
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206